Key result
Antiplatelet agents are established for secondary prevention of atherosclerosis, while their use in primary prevention requires weighing cardiovascular benefits against hemorrhagic risks.
Why the study?
What is the role of antiplatelet agents in the primary and secondary prevention of cardiovascular events in patients with atherosclerotic disease?
Population
Patients with atherosclerotic disease, coronary artery disease, or at risk for cardiovascular events
Design
Review
Authors
Loading...
Supports individualized primary prevention decisions; leaves open updated RCTs in contemporary risk cohorts.
What is the role of antiplatelet agents in the primary and secondary prevention of cardiovascular events in patients with atherosclerotic disease?
This review summarizes contemporary data on the efficacy and safety of antiplatelet agents for primary and secondary prevention of cardiovascular events, emphasizing the need for individualized therapy.
Acharji et al. (2013) conducted a review in Atherosclerotic Disease. Antiplatelet agents was evaluated. Antiplatelet agents are established for secondary prevention of atherosclerosis, while their use in primary prevention requires weighing cardiovascular benefits against hemorrhagic risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: